速递 | 较司美格鲁肽单药减重效果提升56.2%！歌礼新药首项炸裂数据公布

Core Viewpoint - The combination of ASC47 and semaglutide shows significantly better weight loss effects in obese patients compared to semaglutide alone, with improved gastrointestinal tolerance [2][5]. Research Highlights - The ASC47 and semaglutide combination therapy resulted in a weight loss improvement of up to 56.2% compared to the placebo and semaglutide alone [3]. - Specifically, the ASC47-103 study indicated that a single subcutaneous injection of 30 mg ASC47 combined with semaglutide led to a 56.2% relative weight loss improvement, while the 60 mg ASC47 group showed a 15.1% improvement [3]. - Overall, the combination therapy group achieved a 31.6% greater weight loss compared to the semaglutide monotherapy group [3]. Research Methodology - The ASC47-103 study was a randomized, double-blind, placebo-controlled trial assessing the safety, tolerability, and weight loss effects of ASC47 combined with semaglutide in obese patients [4]. - A total of 28 obese patients were included in the study, which lasted for 4 weeks of treatment followed by a 6-week follow-up [4]. Gastrointestinal Tolerance - The combination therapy demonstrated a significantly lower vomiting incidence of 6.7%, compared to 57.1% in the semaglutide monotherapy group, indicating better gastrointestinal tolerance [5]. Weight Maintenance Effect - ASC47 exhibits a long-acting subcutaneous depot characteristic with a half-life of 30 days, significantly reducing weight rebound after discontinuation [6]. - After 4 weeks of discontinuation, the 30 mg ASC47 group showed a 157.1% relative weight loss improvement, while the 60 mg group showed a 110.4% improvement [6]. Safety and Tolerability - The combination therapy of ASC47 and semaglutide showed good safety, with no thyroid-related adverse events observed, and all thyroid function tests remained within normal ranges [7]. - No abnormalities were found in electrocardiogram monitoring, indicating good safety performance of the combination therapy [7]. Future Outlook - The study results provide strong clinical data support for the therapeutic potential of ASC47 combined with semaglutide, with the company planning to advance clinical development for obesity treatment [8].